Anthem Bio Share Price Jumps 5% on Strong Q1 Performance in CRDMO and Specialty Business

Market Performance

Anthem Bio share price surged nearly 5% in today’s trade after the company reported a robust June quarter performance. The rally reflects strong growth in both the CRDMO and Specialty Ingredients businesses, boosting investor sentiment.

Main News

For the quarter ended June 2025, Anthem Biosciences posted consolidated revenue from operations of ₹540 crore, marking a 59% year-on-year increase.

Key financial highlights for Q1 FY26 include:

• Revenue from CRDMO business: Up 70% YoY
• Net profit: ₹135.8 crore, up 65% YoY
• EBITDA: ₹214.3 crore, up 52.7% YoY
• CRDMO contribution: 84% of total revenue in Q1 FY26

The company credited this performance to strong momentum in its CRDMO operations, which began ramping up from Q2 FY25.

Company Details

Anthem Biosciences, a recently listed CRDMO player, has been expanding its manufacturing footprint:

• Unit II, Harohalli: Expansion of 54 kL custom synthesis capacity completed; commercial operations started.
• Unit III: Phased commencement of custom synthesis block, R&D laboratory, pilot lab, kilo lab, and hydrogenation facility.
• Peptide manufacturing: New state-of-the-art facility with 16 kL capacity inaugurated.
• Hi-potent manufacturing: Facility with 2.5 kL capacity launched at Harohalli.
• Unit IV, Harohalli: Construction underway for a greenfield facility spread over 30 acres.

Summary of the Article

Anthem Bio share price gained after the company posted double-digit growth across all key metrics in Q1 FY26. The CRDMO business led the charge, contributing a major share to revenue. With significant capacity additions and new facility launches, Anthem Biosciences is positioned for continued operational growth.